Cargando…
Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data
BACKGROUND & AIMS: Gastrointestinal cancer risk is influenced by the presence of metabolic syndrome (MetS). However, previous epidemiologic studies lacked full serological biomarker data for the classification of MetS, and the interaction of MetS with germline cancer risk variants is unknown. ME...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
W.B. Saunders for the American Gastroenterological Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117007/ https://www.ncbi.nlm.nih.gov/pubmed/34687971 http://dx.doi.org/10.1016/j.cgh.2021.10.016 |
_version_ | 1784710235332542464 |
---|---|
author | Rothwell, Joseph A. Jenab, Mazda Karimi, Mojgan Truong, Thérèse Mahamat-Saleh, Yahya Ferrari, Pietro Dashti, S. Ghazaleh Kühn, Tilman Cross, Amanda J. Severi, Gianluca Gunter, Marc J. Murphy, Neil |
author_facet | Rothwell, Joseph A. Jenab, Mazda Karimi, Mojgan Truong, Thérèse Mahamat-Saleh, Yahya Ferrari, Pietro Dashti, S. Ghazaleh Kühn, Tilman Cross, Amanda J. Severi, Gianluca Gunter, Marc J. Murphy, Neil |
author_sort | Rothwell, Joseph A. |
collection | PubMed |
description | BACKGROUND & AIMS: Gastrointestinal cancer risk is influenced by the presence of metabolic syndrome (MetS). However, previous epidemiologic studies lacked full serological biomarker data for the classification of MetS, and the interaction of MetS with germline cancer risk variants is unknown. METHODS: We investigated the associations between MetS and gastrointestinal cancer risk (overall, colorectal, pancreatic, esophageal adenocarcinoma, esophageal squamous cell carcinoma, stomach cardia, stomach non-cardia, hepatocellular carcinoma, and intrahepatic bile duct cancer) in 366,016 United Kingdom Biobank participants with comprehensive serum biomarker and genotype data. MetS status was determined by 3 different definitions at baseline, and, in 15,152 participants, at a repeat assessment after a median of 4.3 years of follow-up. Multivariable hazard ratios and 95% confidence intervals for cancer outcomes were estimated using Cox proportional hazards models. Analyses stratified by polygenic risk score were conducted for colorectal and pancreatic cancers. RESULTS: During a median follow-up of 7.1 years, 4238 incident cases of a gastrointestinal cancer occurred. MetS at baseline was associated with higher risk of overall gastrointestinal cancer by any definition (hazard ratio, 1.21; 95% confidence interval, 1.13–1.29, harmonized definition). MetS was associated with increased risks of colorectal cancer, colon cancer, rectal cancer, hepatocellular carcinoma, pancreatic cancer in women, and esophageal adenocarcinoma in men. Associations for colorectal cancer and pancreatic cancer did not differ by polygenic risk score strata (P-heterogeneity 0.70 and 0.69, respectively), and 80% of participants with MetS at baseline retained this status at the repeat assessment. CONCLUSIONS: These findings underscore the importance of maintaining good metabolic health in reducing the burden of gastrointestinal cancers, irrespective of genetic predisposition. |
format | Online Article Text |
id | pubmed-9117007 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | W.B. Saunders for the American Gastroenterological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-91170072022-06-14 Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data Rothwell, Joseph A. Jenab, Mazda Karimi, Mojgan Truong, Thérèse Mahamat-Saleh, Yahya Ferrari, Pietro Dashti, S. Ghazaleh Kühn, Tilman Cross, Amanda J. Severi, Gianluca Gunter, Marc J. Murphy, Neil Clin Gastroenterol Hepatol Original Article BACKGROUND & AIMS: Gastrointestinal cancer risk is influenced by the presence of metabolic syndrome (MetS). However, previous epidemiologic studies lacked full serological biomarker data for the classification of MetS, and the interaction of MetS with germline cancer risk variants is unknown. METHODS: We investigated the associations between MetS and gastrointestinal cancer risk (overall, colorectal, pancreatic, esophageal adenocarcinoma, esophageal squamous cell carcinoma, stomach cardia, stomach non-cardia, hepatocellular carcinoma, and intrahepatic bile duct cancer) in 366,016 United Kingdom Biobank participants with comprehensive serum biomarker and genotype data. MetS status was determined by 3 different definitions at baseline, and, in 15,152 participants, at a repeat assessment after a median of 4.3 years of follow-up. Multivariable hazard ratios and 95% confidence intervals for cancer outcomes were estimated using Cox proportional hazards models. Analyses stratified by polygenic risk score were conducted for colorectal and pancreatic cancers. RESULTS: During a median follow-up of 7.1 years, 4238 incident cases of a gastrointestinal cancer occurred. MetS at baseline was associated with higher risk of overall gastrointestinal cancer by any definition (hazard ratio, 1.21; 95% confidence interval, 1.13–1.29, harmonized definition). MetS was associated with increased risks of colorectal cancer, colon cancer, rectal cancer, hepatocellular carcinoma, pancreatic cancer in women, and esophageal adenocarcinoma in men. Associations for colorectal cancer and pancreatic cancer did not differ by polygenic risk score strata (P-heterogeneity 0.70 and 0.69, respectively), and 80% of participants with MetS at baseline retained this status at the repeat assessment. CONCLUSIONS: These findings underscore the importance of maintaining good metabolic health in reducing the burden of gastrointestinal cancers, irrespective of genetic predisposition. W.B. Saunders for the American Gastroenterological Association 2022-06 /pmc/articles/PMC9117007/ /pubmed/34687971 http://dx.doi.org/10.1016/j.cgh.2021.10.016 Text en © 2022 by the AGA Institute. Published by Elsevier Inc. https://creativecommons.org/licenses/by/3.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Original Article Rothwell, Joseph A. Jenab, Mazda Karimi, Mojgan Truong, Thérèse Mahamat-Saleh, Yahya Ferrari, Pietro Dashti, S. Ghazaleh Kühn, Tilman Cross, Amanda J. Severi, Gianluca Gunter, Marc J. Murphy, Neil Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data |
title | Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data |
title_full | Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data |
title_fullStr | Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data |
title_full_unstemmed | Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data |
title_short | Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data |
title_sort | metabolic syndrome and risk of gastrointestinal cancers: an investigation using large-scale molecular data |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117007/ https://www.ncbi.nlm.nih.gov/pubmed/34687971 http://dx.doi.org/10.1016/j.cgh.2021.10.016 |
work_keys_str_mv | AT rothwelljosepha metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT jenabmazda metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT karimimojgan metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT truongtherese metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT mahamatsalehyahya metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT ferraripietro metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT dashtisghazaleh metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT kuhntilman metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT crossamandaj metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT severigianluca metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT guntermarcj metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata AT murphyneil metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata |